Sorafenib - Wikipedia

Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar), is a kinase inhibitor drug approved for the treatment of primary kidney cancer ...

Sorafenib: Indications, Side Effects, Warnings - Drugs.com

Easy-to-read patient leaflet for Sorafenib. Includes indications, proper use, special instructions, precautions, and possible side effects.

Treatment With NEXAVAR (sorafenib)

Learn about NEXAVAR (sorafenib), including how it is thought to work, treatment options, and financial support.

Sorafenib – Wikipedia

Anwendungsgebiete und Zulassung. Sorafenib zählt zu den Orphan-Arzneimitteln und ist seit 2006 für einige wenige Indikationen in der EU zugelassen.

Sorafenib | Cancer information| Cancer Research UK

Sorafenib is a type of targeted cancer drug called a cancer growth blocker. It is a treatment for a certain type of liver and thyroid cancer. Find out how you have it ...

Sorafenib | C21H16ClF3N4O3 - PubChem - The PubChem Project

Sorafenib | C21H16ClF3N4O3 | CID 216239 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities ...

Behandling ved spredning af leverkræft | Kræftens ...

Behandling med stoffet sorafenib kan få sygdommen til at holde sig i ro i en periode. Sorafenib virker ved at hæmme dannelsen af nye blodkar, så kræftcellerne ...

Nexavar® - pro.medicin.dk – information om medicin

Sorafenib bør kun anvendes, når behandlingen forestås af læger med særligt kendskab til maligne lidelser og deres behandling. ...

Sorafenib: MedlinePlus Drug Information

Sorafenib: learn about side effects, dosage, special precautions, and more on MedlinePlus

SORAFENIB | Drug | BNF content published by NICE

Indications, dose, contra-indications, side-effects, interactions, cautions, warnings and other safety information for SORAFENIB.